Tiered Pharmacy Copayments for Medications; Calendar Year 2021 Update, 12788-12790 [2021-04458]
Download as PDF
<![CDATA[
12788
Federal Register / Vol. 86, No. 41 / Thursday, March 4, 2021 / Notices
questions is April 19, 2021.
Applications and other information
regarding the CDFI Fund and its
programs may be obtained from the
CDFI Fund’s website at https://
www.cdfifund.gov. The CDFI Fund will
post on its website responses to
questions of general applicability
regarding the CDFI Bond Guarantee
Program.
B. The CDFI Fund’s contact
information is as follows:
TABLE 2—CONTACT INFORMATION
Telephone number
(not toll free)
Type of question
CDFI Bond Guarantee Program ........................................................................................
CDFI Certification ...............................................................................................................
Certification, Compliance Monitoring and Evaluation ........................................................
Information Technology Support ........................................................................................
C. Communication with the CDFI
Fund. The CDFI Fund will
communicate with applicants, Qualified
Issuers, Program Administrators,
Servicers, Certified CDFIs and Eligible
CDFIs, using the contact information
maintained in their respective AMIS
accounts. Therefore, each such entity
must maintain accurate contact
information (including contact person
and authorized representative, email
addresses, fax numbers, phone numbers,
and office addresses) in its respective
AMIS account. For more information
about AMIS, please see the AMIS
Landing Page at https://
amis.cdfifund.gov.
VII. Information Sessions and Outreach
The CDFI Fund may conduct
webcasts, webinars, or information
sessions for organizations that are
considering applying to, or are
interested in learning about, the CDFI
Bond Guarantee Program. The CDFI
Fund intends to provide targeted
outreach to both Qualified Issuer and
Eligible CDFI participants to clarify the
roles and requirements under the CDFI
Bond Guarantee Program. For further
information, or to sign up for alerts,
please visit the CDFI Fund’s website at
https://www.cdfifund.gov.
Authority: Pub. L. 111–240; 12 U.S.C.
4701, et seq.; 12 CFR part 1808; 12 CFR part
1805;12 CFR part 1815.
Jodie L. Harris,
Director, Community Development Financial
Institutions Fund.
[FR Doc. 2021–04429 Filed 3–3–21; 8:45 am]
jbell on DSKJLSW7X2PROD with NOTICES
BILLING CODE 4810–70–P
U.S.-CHINA ECONOMIC AND
SECURITY REVIEW COMMISSION
Notice of Open Public Hearing
U.S.-China Economic and
Security Review Commission.
ACTION: Notice of open public hearing.
AGENCY:
VerDate Sep<11>2014
20:27 Mar 03, 2021
Jkt 253001
(202)
(202)
(202)
(202)
653–0421
653–0423
653–0423
653–0422
Notice is hereby given of the
following hearing of the U.S.-China
Economic and Security Review
Commission. The Commission is
mandated by Congress to investigate,
assess, and report to Congress annually
on ‘‘the national security implications of
the economic relationship between the
United States and the People’s Republic
of China.’’ Pursuant to this mandate, the
Commission will hold a public hearing
in Washington, DC, on March 19, 2021,
on ‘‘U.S. Investment in China’s Capital
Markets and Military-Industrial
Complex.’’
SUMMARY:
The hearing is scheduled for
Friday, March 19, 2021, 9:15 a.m.
ADDRESSES: This hearing will be held
with panelists and Commissioners
participating in-person or online via
videoconference. Members of the
audience will be able to view a live
webcast via the Commission’s website at
www.uscc.gov. Also, please check the
Commission’s website for possible
changes to the hearing schedule.
Reservations are not required to attend
the hearing.
FOR FURTHER INFORMATION CONTACT: Any
member of the public seeking further
information concerning the hearing
should contact Jameson Cunningham,
444 North Capitol Street NW, Suite 602,
Washington DC 20001; telephone: 202–
624–1496, or via email at jcunningham@
uscc.gov. Reservations are not required
to attend the hearing.
ADA Accessibility: For questions
about the accessibility of the event or to
request an accommodation, please
contact Jameson Cunningham via email
at jcunningham@uscc.gov. Requests for
an accommodation should be made as
soon as possible, and at least five
business days prior to the event.
SUPPLEMENTARY INFORMATION:
Background: This is the third public
hearing the Commission will hold
during its 2021 report cycle. The
hearing will examine the Chinese
government’s use of capital markets to
advance its technology and defense
DATES:
PO 00000
Frm 00196
Fmt 4703
Sfmt 4703
Option 5
.............
.............
.............
Email addresses
bgp@cdfi.treas.gov.
ccme@cdfi.treas.gov.
ccme@cdfi.treas.gov.
AMIS@cdfi.treas.gov.
capabilities and evaluate the risks of
U.S. investors’ capital being leveraged
for such ends. The opening panel will
examine the evolving role of the state in
China’s capital markets, including the
Chinese Communist Party’s
involvement in corporate governance.
The second panel will review China’s
financial opening and U.S. and foreign
investor participation in China’s capital
markets. The third panel will assess
U.S. national security risks posed by
investment in Chinese companies. The
fourth panel will evaluate U.S. legal
authority and current restrictions on
outbound investment to China’s capital
markets.
The hearing will be co-chaired by
Commissioner Robert Borochoff and
Commissioner Jeffrey Fiedler. Any
interested party may file a written
statement by March 19, 2021 by
transmitting to the contact above. A
portion of the hearing will include a
question and answer period between the
Commissioners and the witnesses.
Authority: Congress created the U.S.-China
Economic and Security Review Commission
in 2000 in the National Defense
Authorization Act (Pub. L. 106–398), as
amended by Division P of the Consolidated
Appropriations Resolution, 2003 (Pub. L.
108–7), as amended by Public Law 109–108
(November 22, 2005), as amended by Public
Law 113–291 (December 19, 2014).
Dated: March 1, 2021.
Daniel W. Peck,
Executive Director, U.S.-China Economic and
Security Review Commission.
[FR Doc. 2021–04507 Filed 3–3–21; 8:45 am]
BILLING CODE 1137–00–P
DEPARTMENT OF VETERANS
AFFAIRS
Tiered Pharmacy Copayments for
Medications; Calendar Year 2021
Update
Department of Veterans Affairs.
Notice.
AGENCY:
ACTION:
E:\FR\FM\04MRN1.SGM
04MRN1
Federal Register / Vol. 86, No. 41 / Thursday, March 4, 2021 / Notices
This Department of Veterans
Affairs (VA) Notice updates the
information on Tier 1 medications.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Joseph Duran, Office of Community
Care, Veterans Health Administration,
Department of Veterans Affairs, 810
Vermont Avenue NW, Washington, DC
20420; Joseph.Duran2@va.gov; 303–
370–1637. This is not a toll-free number.
Section
17.110 of title 38, CFR, governs
copayments for medications that VA
provides to veterans. Section 17.110
provides the methodologies for
establishing the copayment amount for
SUPPLEMENTARY INFORMATION:
each 30-day or less supply of
medication provided by VA on an
outpatient basis (other than medication
administered during treatment).
Tier 1 medication means a multisource medication that has been
identified using the process described in
paragraph (b)(2) of this section. Not less
than once per year, VA will identify a
subset of multi-source medications as
Tier 1 medications. Only medications
that meet all of the criteria in 38 CFR
17.110(b)(2)(i), (ii), and (iii) will be
eligible to be considered Tier 1
medications, and only those
medications that meet all of the criteria
in paragraph (b)(2)(i) of this section will
Condition
Blood Thinners and Platelet Inhibitors ................
Bone Health ........................................................
Cholesterol ..........................................................
Dementia .............................................................
Diabetes ..............................................................
Electrolyte Supplement .......................................
Gastrointestinal Health ........................................
Glaucoma and Eye Care .....................................
jbell on DSKJLSW7X2PROD with NOTICES
Heart Health and Blood Pressure .......................
VerDate Sep<11>2014
20:27 Mar 03, 2021
be assessed using the criteria in
paragraphs (b)(2)(ii) and (iii).
Based on the methodologies set forth
in § 17.110, this notice updates the list
of Tier 1 medications for Calendar Year
2021. The Tier 1 medication list is
posted on VA’s Community Care
website at the following link: https://
www.va.gov/COMMUNITYCARE/
revenue_ops/copays.asp under the
heading ‘‘Tier 1 Copay Medication
List.’’
The following table is the Tier 1
Copay Medication List that is effective
January 1, 2021 and will remain in
effect until December 31, 2021.
VA product name
Arthritis and Pain .................................................
Jkt 253001
Aspirin Buffered Tablet.
Aspirin Chewable Tablet.
Aspirin Enteric Coated Tablet.
Allopurinol Tablet.
Celecoxib Capsule.
Diclofenac Tablet.
Ibuprofen Tablet.
Meloxicam Tablet.
Naproxen Tablet.
Clopidogrel Bisulfate Tablet.
Warfarin Sodium Tablet.
Alendronate Tablet.
Atorvastatin Tablet.
Ezetimibe Tablet.
Pravastatin Tablet.
Rosuvastatin Calcium Tablet.
Simvastatin Tablet.
Donepezil Tablet.
Glimepiride Tablet.
Glipizide Tablet.
Metformin Hydrochloride (HCL) Tablet.
Metformin HCL 24-Hour Sustained Action (SA) Tablet.
Pioglitazone HCL Tablet.
Potassium SA Tablet.
Potassium SA dispersible Tablet.
Famotidine Tablet.
Omeprazole Enteric Coated (EC) Capsule.
Pantoprazole Sodium EC Capsule.
Diclofenac Solution.
Dorzolamide 2%/Timolol 0.5% Solution.
Latanoprost 0.005% Solution.
Polyethylene Glycol 400/Polyethylene Glycol 4000 Solution.
Carboxymethylcellulose Sodium Solution.
Amlodipine Tablet.
Amiodarone HCL Tablet.
Aspirin (see Arthritis and Pain).
Atenolol Tablet.
Carvedilol Tablet.
ChlorthalidoneTablet.
Clonidine Tablet.
Diltiazem 24-Hour Capsule.
Diltiazem HCL Tablet.
Enalapril Maleate Tablet.
Furosemide Tablet.
Hydralazine HCL Tablet.
Hydrochlorothiazide Tablet/Capsule.
Hydrochlorothiazide/Lisinopril Tablet.
Hydrochlorothiazide/Losartan Tablet.
Hydrochlorothiazide/Triamterene Tablet/Capsule.
Isosorbide Mononitrate SA Tablet.
Lisinopril Tablet.
Losartan Tablet.
Metoprolol Succinate SA Tablet.
Metoprolol Tartrate Tablet.
Nifedipine SA Capsule.
PO 00000
Frm 00197
Fmt 4703
Sfmt 4703
12789
E:\FR\FM\04MRN1.SGM
04MRN1
12790
Federal Register / Vol. 86, No. 41 / Thursday, March 4, 2021 / Notices
Condition
VA product name
Mental Health ......................................................
Respiratory Condition ..........................................
Seizures ..............................................................
Thyroid Conditions ..............................................
Urologic (Bladder and Prostate) Health ..............
Signing Authority
Denis McDonough, Secretary of
Veterans Affairs, approved this
document on February 26, 2021, and
Nitroglycerin sublingual Tablet.
Prazosin HCL Capsule.
Propranolol HCL Tablet.
Spironolactone Tablet.
Amitriptyline HCL Tablet.
Buspirone HCL Tablet.
Bupropion HCL Tablet.
Bupropion HCL SA (12HR–SR) Tablet.
Bupropion HCL SA (24HR–XL) Tablet.
Citalopram Hydrobromide Tablet.
Duloxetine HCL EC Capsule.
Escitalopram Oxalate Tablet.
Fluoxetine Tablet/Capsule.
Mirtazapine Tablet.
Paroxetine Tablet.
Sertraline HCL Tablet.
Trazodone Tablet.
Venlafaxine HCL Immediate (IR) Tablet.
Venlafaxine HCL SA Capsule.
Montelukast NA Tablet.
Gabapentin Capsule.
Lamotrigine Tablet.
Topiramate Tablet.
Levothyroxine Sodium Tablet.
Alfuzosin HCL SA Tablet.
Doxazosin Mesylate Tablet.
Finasteride Tablet.
Oxybutynin Chloride IR Tablet.
Oxybutynin Chloride SA Tablet.
Sildenafil Tablet.
Tamsulosin HCL Capsule.
Terazosin HCL Capsule.
authorized the undersigned to sign and
submit the document to the Office of the
Federal Register for publication
electronically as an official document of
the Department of Veterans Affairs.
Luvenia Potts,
Regulation Development Coordinator, Office
of Regulation Policy & Management, Office
of the Secretary, Department of Veterans
Affairs.
[FR Doc. 2021–04458 Filed 3–3–21; 8:45 am]
jbell on DSKJLSW7X2PROD with NOTICES
BILLING CODE 8320–01–P
VerDate Sep<11>2014
20:27 Mar 03, 2021
Jkt 253001
PO 00000
Frm 00198
Fmt 4703
Sfmt 9990
E:\FR\FM\04MRN1.SGM
04MRN1
]]>Agencies
[Federal Register Volume 86, Number 41 (Thursday, March 4, 2021)]
[Notices]
[Pages 12788-12790]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-04458]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF VETERANS AFFAIRS
Tiered Pharmacy Copayments for Medications; Calendar Year 2021
Update
AGENCY: Department of Veterans Affairs.
ACTION: Notice.
-----------------------------------------------------------------------
[[Page 12789]]
SUMMARY: This Department of Veterans Affairs (VA) Notice updates the
information on Tier 1 medications.
FOR FURTHER INFORMATION CONTACT: Joseph Duran, Office of Community
Care, Veterans Health Administration, Department of Veterans Affairs,
810 Vermont Avenue NW, Washington, DC 20420; [email protected]; 303-
370-1637. This is not a toll-free number.
SUPPLEMENTARY INFORMATION: Section 17.110 of title 38, CFR, governs
copayments for medications that VA provides to veterans. Section 17.110
provides the methodologies for establishing the copayment amount for
each 30-day or less supply of medication provided by VA on an
outpatient basis (other than medication administered during treatment).
Tier 1 medication means a multi-source medication that has been
identified using the process described in paragraph (b)(2) of this
section. Not less than once per year, VA will identify a subset of
multi-source medications as Tier 1 medications. Only medications that
meet all of the criteria in 38 CFR 17.110(b)(2)(i), (ii), and (iii)
will be eligible to be considered Tier 1 medications, and only those
medications that meet all of the criteria in paragraph (b)(2)(i) of
this section will be assessed using the criteria in paragraphs
(b)(2)(ii) and (iii).
Based on the methodologies set forth in Sec. 17.110, this notice
updates the list of Tier 1 medications for Calendar Year 2021. The Tier
1 medication list is posted on VA's Community Care website at the
following link: https://www.va.gov/COMMUNITYCARE/revenue_ops/copays.asp
under the heading ``Tier 1 Copay Medication List.''
The following table is the Tier 1 Copay Medication List that is
effective January 1, 2021 and will remain in effect until December 31,
2021.
------------------------------------------------------------------------
Condition VA product name
------------------------------------------------------------------------
Arthritis and Pain................ Aspirin Buffered Tablet.
Aspirin Chewable Tablet.
Aspirin Enteric Coated Tablet.
Allopurinol Tablet.
Celecoxib Capsule.
Diclofenac Tablet.
Ibuprofen Tablet.
Meloxicam Tablet.
Naproxen Tablet.
Blood Thinners and Platelet Clopidogrel Bisulfate Tablet.
Inhibitors.
Warfarin Sodium Tablet.
Bone Health....................... Alendronate Tablet.
Cholesterol....................... Atorvastatin Tablet.
Ezetimibe Tablet.
Pravastatin Tablet.
Rosuvastatin Calcium Tablet.
Simvastatin Tablet.
Dementia.......................... Donepezil Tablet.
Diabetes.......................... Glimepiride Tablet.
Glipizide Tablet.
Metformin Hydrochloride (HCL)
Tablet.
Metformin HCL 24-Hour Sustained
Action (SA) Tablet.
Pioglitazone HCL Tablet.
Electrolyte Supplement............ Potassium SA Tablet.
Potassium SA dispersible Tablet.
Gastrointestinal Health........... Famotidine Tablet.
Omeprazole Enteric Coated (EC)
Capsule.
Pantoprazole Sodium EC Capsule.
Glaucoma and Eye Care............. Diclofenac Solution.
Dorzolamide 2%/Timolol 0.5%
Solution.
Latanoprost 0.005% Solution.
Polyethylene Glycol 400/Polyethylene
Glycol 4000 Solution.
Carboxymethylcellulose Sodium
Solution.
Heart Health and Blood Pressure... Amlodipine Tablet.
Amiodarone HCL Tablet.
Aspirin (see Arthritis and Pain).
Atenolol Tablet.
Carvedilol Tablet.
ChlorthalidoneTablet.
Clonidine Tablet.
Diltiazem 24-Hour Capsule.
Diltiazem HCL Tablet.
Enalapril Maleate Tablet.
Furosemide Tablet.
Hydralazine HCL Tablet.
Hydrochlorothiazide Tablet/Capsule.
Hydrochlorothiazide/Lisinopril
Tablet.
Hydrochlorothiazide/Losartan Tablet.
Hydrochlorothiazide/Triamterene
Tablet/Capsule.
Isosorbide Mononitrate SA Tablet.
Lisinopril Tablet.
Losartan Tablet.
Metoprolol Succinate SA Tablet.
Metoprolol Tartrate Tablet.
Nifedipine SA Capsule.
[[Page 12790]]
Nitroglycerin sublingual Tablet.
Prazosin HCL Capsule.
Propranolol HCL Tablet.
Spironolactone Tablet.
Mental Health..................... Amitriptyline HCL Tablet.
Buspirone HCL Tablet.
Bupropion HCL Tablet.
Bupropion HCL SA (12HR-SR) Tablet.
Bupropion HCL SA (24HR-XL) Tablet.
Citalopram Hydrobromide Tablet.
Duloxetine HCL EC Capsule.
Escitalopram Oxalate Tablet.
Fluoxetine Tablet/Capsule.
Mirtazapine Tablet.
Paroxetine Tablet.
Sertraline HCL Tablet.
Trazodone Tablet.
Venlafaxine HCL Immediate (IR)
Tablet.
Venlafaxine HCL SA Capsule.
Respiratory Condition............. Montelukast NA Tablet.
Seizures.......................... Gabapentin Capsule.
Lamotrigine Tablet.
Topiramate Tablet.
Thyroid Conditions................ Levothyroxine Sodium Tablet.
Urologic (Bladder and Prostate) Alfuzosin HCL SA Tablet.
Health.
Doxazosin Mesylate Tablet.
Finasteride Tablet.
Oxybutynin Chloride IR Tablet.
Oxybutynin Chloride SA Tablet.
Sildenafil Tablet.
Tamsulosin HCL Capsule.
Terazosin HCL Capsule.
------------------------------------------------------------------------
Signing Authority
Denis McDonough, Secretary of Veterans Affairs, approved this
document on February 26, 2021, and authorized the undersigned to sign
and submit the document to the Office of the Federal Register for
publication electronically as an official document of the Department of
Veterans Affairs.
Luvenia Potts,
Regulation Development Coordinator, Office of Regulation Policy &
Management, Office of the Secretary, Department of Veterans Affairs.
[FR Doc. 2021-04458 Filed 3-3-21; 8:45 am]
BILLING CODE 8320-01-P
